MOLECULAR DESCRIPTORS ENHANCEMENT OF A COMMON STRUCTURE TOWARDS THE DEVELOPMENT OF α-GLUCOSIDASE AND α-AMYLASE INHIBITORS FOR POST-PRANDIAL HYPERGLYCEMIA (PPHG)

S. Prasanth Kumar*¹, Ravi G. Kapopara*¹, Saumya K. Patel¹,Yogesh T. Jasrai¹, Himanshu A. Pandya¹ and Rakesh M. Rawal²

¹Bioinformatics Laboratory, Department of Botany, University School of Sciences, Gujarat University, Ahmedabad-380 009.

²Division of Cancer Biology, Department of Medicinal Chemistry and Pharmacogenomics, Gujarat Cancer and Research Institute (GCRI), Ahmedabad- 380016.

Please navigate to this page for full text article: http://jbiopharm.com/index.php/ajpsbr/article/view/39



ABSTRACT:

The most challenging goal in the management of diabetic patient is to achieve normal blood glucose levels caused by post-prandial hyperglycemia (PPHG) or hyperinsulinemia, the individual risk factor contributes to the development of macrovascular complications. Synthetic hypoglycemic agents are available which has its own limitations and serious side-effects. The present study deals about the development of a common small molecular structure by enhancing the molecular descriptors required for binding with α-glucosidase and α-amylase enzymes, the two major targets of PPHG and to develop a monosaccharide-type inhibitor with many insights derived from pharmacophore studies, molecular alignment and molecular docking studies of known inhibitors. An hypothesis was designed which suggest the essential and/or minimal requirement of molecular descriptors in order to be an efficient binder of these two hydrolytic enzymes and subsequently, molecules with naturally occurring flavonoid structural architecture obeying the hypothesis was developed and evaluated in silico.